CureVac N.V. (5CV.F)
EUR 2.86
(1.63%)
EUR 2.86
(1.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 788.89 Million EUR | -8.32% |
| 2022 | 860.47 Million EUR | -25.71% |
| 2021 | 1.15 Billion EUR | -23.36% |
| 2020 | 1.51 Billion EUR | 1057.06% |
| 2019 | 130.62 Million EUR | 3.95% |
| 2018 | 125.65 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 557.16 Million EUR | -19.35% |
| 2024 Q1 | 690.43 Million EUR | -12.48% |
| 2023 Q2 | 899.48 Million EUR | -7.62% |
| 2023 FY | 788.89 Million EUR | -8.32% |
| 2023 Q1 | 973.67 Million USD | 13.16% |
| 2023 Q3 | 842.56 Million EUR | -6.33% |
| 2023 Q4 | 788.89 Million EUR | -6.37% |
| 2022 Q3 | 910.51 Million EUR | -1.65% |
| 2022 Q2 | 925.82 Million EUR | -9.82% |
| 2022 Q1 | 1.02 Billion EUR | -11.36% |
| 2022 FY | 860.47 Million EUR | -25.71% |
| 2022 Q4 | 860.47 Million EUR | -5.5% |
| 2021 Q4 | 1.15 Billion EUR | -30.36% |
| 2021 Q3 | 1.66 Billion EUR | -7.66% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 FY | 1.15 Billion EUR | -23.36% |
| 2021 Q2 | 1.8 Billion EUR | 0.0% |
| 2020 Q1 | 155.65 Million EUR | 19.17% |
| 2020 Q4 | 1.51 Billion EUR | 47.9% |
| 2020 Q3 | 1.02 Billion EUR | 0.0% |
| 2020 Q2 | - EUR | -100.0% |
| 2020 FY | 1.51 Billion EUR | 1057.06% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 FY | 130.62 Million EUR | 3.95% |
| 2019 Q4 | 130.62 Million EUR | 0.0% |
| 2018 FY | 125.65 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| BioNTech SE | 23 Billion EUR | 96.571% |
| Biotest Aktiengesellschaft | 1.44 Billion EUR | 45.378% |
| Biotest Aktiengesellschaft | 1.44 Billion EUR | 45.378% |
| BRAIN Biotech AG | 70.93 Million EUR | -1012.112% |
| Formycon AG | 890.36 Million EUR | 11.396% |
| Heidelberg Pharma AG | 70.35 Million EUR | -1021.343% |
| Medigene AG | 31.71 Million EUR | -2387.385% |